ID   MV-4-11B
AC   CVCL_C3HG
SY   MV-4-11-B; MV-4-11b
DR   cancercelllines; CVCL_C3HG
DR   GEO; GSE103068
DR   GEO; GSM2716693
DR   GEO; GSM2716694
DR   GEO; GSM2716695
DR   GEO; GSM2716696
DR   GEO; GSM2716697
DR   GEO; GSM2716698
DR   GEO; GSM2716699
DR   GEO; GSM2716700
DR   GEO; GSM2716701
DR   GEO; GSM2716702
DR   GEO; GSM2716703
DR   GEO; GSM2716704
DR   GEO; GSM2716705
DR   GEO; GSM2716706
DR   GEO; GSM2716707
DR   GEO; GSM2716713
DR   GEO; GSM2716714
DR   GEO; GSM2716715
DR   GEO; GSM2716716
DR   GEO; GSM2716717
DR   GEO; GSM2716718
DR   GEO; GSM2716719
DR   GEO; GSM2716720
DR   GEO; GSM2716721
DR   GEO; GSM2716722
DR   GEO; GSM2716723
DR   GEO; GSM2716724
DR   GEO; GSM2716725
DR   GEO; GSM2716726
DR   GEO; GSM2716727
DR   GEO; GSM2716728
DR   GEO; GSM2716729
DR   GEO; GSM2716730
DR   GEO; GSM2716731
DR   GEO; GSM2716732
DR   GEO; GSM2716733
DR   GEO; GSM2716734
DR   GEO; GSM2716735
DR   GEO; GSM2716736
DR   GEO; GSM2716737
DR   GEO; GSM2716738
DR   GEO; GSM2716739
DR   GEO; GSM2716752
DR   GEO; GSM2716753
DR   GEO; GSM2716754
DR   GEO; GSM2716755
DR   GEO; GSM2716756
DR   GEO; GSM2716757
DR   GEO; GSM2716758
DR   GEO; GSM2716759
DR   GEO; GSM2716760
DR   GEO; GSM2716761
DR   GEO; GSM2716762
DR   GEO; GSM2716763
DR   GEO; GSM2716764
DR   GEO; GSM2716765
DR   GEO; GSM2716766
DR   GEO; GSM2716767
DR   GEO; GSM2716768
DR   GEO; GSM2716769
DR   GEO; GSM2832581
DR   GEO; GSM2832582
DR   GEO; GSM2832583
DR   GEO; GSM2832584
DR   GEO; GSM2832585
DR   GEO; GSM2832586
DR   GEO; GSM2832587
DR   GEO; GSM2832588
DR   GEO; GSM2832589
DR   GEO; GSM2832590
DR   GEO; GSM2832591
DR   GEO; GSM2832592
DR   GEO; GSM2832593
DR   GEO; GSM2832594
DR   Wikidata; Q114312330
RX   PubMed=29491412;
RX   PubMed=29454094;
CC   Population: Caucasian.
CC   Sequence variation: Gene fusion; HGNC; 7135; AFF1 + HGNC; 7132; KMT2A; Name(s)=KMT2A-AFF1, MLL-AFF1, ALL-1/AF4 (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 3765; FLT3; Unexplicit; Internal tandem duplication (FLT3-ITD); ClinVar=VCV000016270; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Heterozygous (PubMed=29491412; PubMed=29454094).
CC   Omics: BRD4 ChIP-seq epigenome analysis.
CC   Omics: Pol2 ChIP-seq epigenome analysis.
CC   Omics: H3K27ac ChIP-seq epigenome analysis.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
DI   NCIt; C9163; Childhood acute monocytic leukemia
DI   ORDO; Orphanet_514; Acute monoblastic/monocytic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0064 ! MV4-11
SX   Male
AG   10Y
CA   Cancer cell line
DT   Created: 22-09-22; Last updated: 05-10-23; Version: 5
//
RX   PubMed=29491412; DOI=10.1038/s41388-018-0150-2;
RA   Gerlach D., Tontsch-Grunt U., Baum A., Popow J., Scharn D.,
RA   Hofmann M.H., Engelhardt H., Kaya O., Beck J., Schweifer N.,
RA   Gerstberger T., Zuber J., Savarese F., Kraut N.;
RT   "The novel BET bromodomain inhibitor BI 894999 represses
RT   super-enhancer-associated transcription and synergizes with CDK9
RT   inhibition in AML.";
RL   Oncogene 37:2687-2701(2018).
//
RX   PubMed=29454094; DOI=10.1016/j.canlet.2018.02.018;
RA   Tontsch-Grunt U., Rudolph D., Waizenegger I.C., Baum A., Gerlach D.,
RA   Engelhardt H., Wurm M., Savarese F., Schweifer N., Kraut N.;
RT   "Synergistic activity of BET inhibitor BI 894999 with PLK inhibitor
RT   volasertib in AML in vitro and in vivo.";
RL   Cancer Lett. 421:112-120(2018).
//